Early detection of prostate cancer in the ESRD population

Clinical Nephrology

Volumn 61, Issue 5, 2004, Pages 308-315

  Khairullah, Q T ^a   Pamatmat, S D ^a   Chatha, M ^a   Provenzano, R ^a   Telang, D ^a   Temple, M ^a  

^a ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

ESRD; Prostate cancer; PSA; PSAD; TRUS

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SCREENING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; INTERMETHOD COMPARISON; KIDNEY FAILURE; MALE; ORGAN SIZE; POPULATION RESEARCH; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY; UROGENITAL SYSTEM EXAMINATION;

EID: 2342520033     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP61308     Document Type: Article

References (59)

1. Babaian R, Mettlin C, Kane R, Murphy G, Lee F, Drago J, Chesley A 1992 The relationship of prostate-specific antigen to digital rectal examination and transrectal ultrasonography. Cancer 69: 1195-1200
2. Bazinet M, Meshref AW, Trudel C, Aronson S, Peloquin F, Nachabe M, Begin L, Elhilali M 1994 Prospective evaluation of prostate-specific antigen density and systemic biopsies for early detection of prostate carcinoma. Urology 43: 44-52
3. Beduschi MC, Oesterling JE 1997 Prostate-specific antigen density. Urol Clin North Am 24: 323-332
4. Benson M, Whang I, Pantuck A, Ring K, Kaplan S, Olsson C, Cooner W 1992 Prostate-specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 147: 815-816
5. Bostwick D, Brawer MK 1987 Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer 59: 788-794
6. Bostwick D 1995 High grade intra-epithelial neoplasia: the most likely precursor on prostate cancer. Cancer 75: 1823-1836
7. Bostwick DG 1999 Prostatic intra-epithelial neoplasia is a risk factor for cancer. Semin Urol Oncol 17: 187-198
8. Brawer MK, Bigler S, Sohlberg O, Nagle R, Lange P 1991 Significance of prostatic intra-epithelial neoplasia on prostate needle biopsy. Urology 38: 103-107
9. Brawer MK, Aramburu EAG, Chen GL, Preston S, Ellis W 1993 The inability of prostate-specific antigen index to enhance the predictive value of prostate-specific antigen in the diagnosis of prostate carcinoma. J Urol 150: 369-373
10. Brawer MK 1999 Prostate-specific antigen: current status. CA Cancer J Clin 49: 264-281
11. Buccianti G, Maisonneuve P, Ravasi B, Cresser D, Locatelli F, Boyle P 1996 Cancer among patients on renal replacement therapy: A population based survey in Lombardy, Italy. Int J Cancer 66: 591-593
12. Carroll P, Coley C, McLeod D, Schellhammer P, Sweat G, Wasson J, Zietman A, Thompson I 2001 Prostate-specific antigen best practice policy: Part I: early detection and diagnosis of prostate cancer. Urology 57: 217-224
13. Catalona W, Smith DS, Ratliff T, Dodds K, Coplen D, Yuan J, Petros J, Andride G 1991 Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. NEJM 324: 1156-1161
14. Catalona W, Richie J, Ahmann F, Hudson M, Scardino P, Flanigan R, DeKarnion J, Ratliff T, Kavoussi L, MacFarlene M, Southwick P 1994a Comparison of digital rectal examination and prostate-specific antigen in early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151: 1283-1290
15. Catalona W, Richie J, DeKernion J, Ahmann F, Ratliff T, Dalkin B, Kavoussi L, MacFarlene M, Southwick P 1994b Comparison of prostate-specific antigen concentration versus prostate-specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol 152: 2031-2036
16. Catalona W, Smith D, Ornstein D 1997 Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination: enhancement of specificity with free PSA measurement. JAMA 277: 1452-1455
17. Chan T, Epstein J 1999 Follow-up of atypical prostate needle biopsies suspicious of cancer. Urology 53: 351-355
18. Chertow GM, Paltiel D, Owen WF, Lazarus M 1996 Cost effectiveness of cancer screening in end-stage renal disease. Arch Intern Med 156: 1345-1350
19. Chodak GW 1988 Transrectal ultrasonography: is it ready for routine use? JAMA 259: 2744-2745
20. Cooner W, Mosley B, Rutherford C, Beard J, Pond H, Bass B, Terry W 1988 Clinical application of transrectal ultrasonography and prostate-specific antigen in the search for prostate cancer. J Urol 139: 758-761
21. Cooner W, Mosley B, Rutherford C, Beard J, Pond H, Terry W, Igel T, Kidd D 1990 Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate-specific antigen. J Urol 143: 1146-1152
22. Daugirdas JT, Ing TS 1994 Handbook of Dialysis (edition 2). Little Brown, Boston, MA
23. Davidson D, Bostwick D, Qian J, Wollan P, Oesterling J, Rudders R, Siroky M, Stilmant M 1995 Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. J Urol 154: 1295-1299
24. Deliveliotis C, Louras G, Raptidis G, Giannakopoulos S, Kastriotis J, Kostakopoules A 1998 Evaluation of needle biopsy in the diagnosis of prostatic carcinoma in men with prostatic intra-epithelial neoplasia. Scand J Urology Nephrology 32: 107-110
25. Djavan B, Remzi M, Zlotta A, Seitz C, Wolfram R, Hruby S, Bursa B, Schulman CC, Marberger M 1999a Combination and multivariate analysis of PSA-based parameters for prostate cancer prediction. Tech Urol 5: 71-76
26. Djavan B, Shariat S, Ghawidel K, Güven-Marberger K, Remzi R, Kovarik J, Hoerl W, Marberger M 1999b Impact of chronic dialysis on serum PSA, free PSA, and free/total PSA ratio: is prostate cancer detection compromised in patients receiving long term dialysis? Urology 53: 1169-1174
27. Djavan B, Zlotta A, Kratzik, Remzi M, Seitz C, Schulman CC, Marberger M 1999c PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/ml. Urology 54: 517-522
28. Ellis W, Brawer MK 1995 Repeat needle biopsy: who needs it? J Urology 153: 1496-1498
29. Feneley M, Green J, Young M, Bose P, Kirby RS, Peeling WB, Parkinson MC 1997 Prevalence of prostatic intraepithelial neoplasia in biopsies from hospital practice and pilot screening: clinical implications. Prostate Cancer Prostatic Diseases 1: 79-83
30. Filella X, Cases A, Molina R, Jo J, Bedini JL, Revert L, Ballesta AM 1990 Tumor markers in patients with chronic renal failure. Int J Biol Markers 5: 85-88
31. Freid R, Davis N, Weiss G 1997 Prostate cancer screening and management. Med Clin North Am 81: 802-822
32. Friedman G, Hiatt R, Quesenberry CP, Selby JV 1991 Case control study of screening for prostatic cancer by digital rectal exam. Lancet 337: 1526-1529
33. Harper L, McIntyre IC, MacDougall IC, Meyer P, Raine AEG, Baker LRI 1995 Prostate-specific antigen levels in patients receiving long-term dialysis. Br J Urol 76: 482-483
34. Hodge K, McNeal J, Terris M, Stamey TA 1989 Random-systematic versus directed ultrasound- guided transrectal core biopsies of the prostate. J Urol 142: 71-74
35. Hoedemacker R, Kranse R, Riethergen J, Kruger A, Schröder F, Van der Kwast T 1999 Evaluation of prostate needle biopsies in a population-based screening study: impact of borderline lesions. Cancer 85: 145-152
36. Holley J 2000 Preventive medical screening is not appropriate for many chronic dialysis patients. Semin Dial 13: 369-371
37. Inamoto H, Yashisuke I, Kazuko S, Ino Y, Sata K, Ozaki R 1983 High-risk ratio on mortality and characteristics of malignancies in dialysis patients. Clin Exp Dial Apheresis 7: 219-224
38. Inamoto H, Ozaki R, Matsuzaki T, Wakui M, Saruta T, Osawa A 1991 Incidence and mortality pattern of malignancy and factors affecting the risk of malignancy in dialysis patients. Nephron 59: 611-617
39. LeBrun C, Diehl L, Abbott K, Welch P, Yuan C 2000 Life expectancy benefits of cancer screening in the end-stage renal disease population. Am J Kidney Disease 35: 237-243
40. Lee F, Littrup P, Torp-Pedersen S, Mettlin C, McHugh T, Gray J, Kumasaka G, McLeary R 1988 Prostate cancer: comparison of transrectal ultrasound and digital rectal exam for screening. Radiology 168: 389-394
41. Lee F, Torp-Pedersen S, Siders D, Littrup P, McLeary R 1989 Transrectal ultrasound in the diagnosis and staging of prostatic carcinoma. Radiology 170: 609-615
42. Mahmood K, Rasgon S, Yeoh HH 1994 Difficult management problems in dialysis: health screening. Semin Dial 7: 48-49
43. Marple JT, Mac Dougall M 1993 Development of malignancy in end-stage renal disease patient. Semin Nephrol 13: 306-314
44. Mettlin C, Jones G, Averette H, Gusberg S, Murphy G 1993 Defining and updating the ACS guidelines for the cancer-related check up, prostate and endometrial cancer. Cancer J Clin 43: 42-46
45. Miller B, Reis L, Hankey B et al 1993 SEER Cancer Statistics Review: 1973-1990. Publication No. 93-2789. National Cancer Institute, National Institute of Health, Bethesda, MD
46. Morton J, Howe S, Lowell J, Stratta RJ, Taylor RJ 1995 Influence of end-stage renal disease and renal transplantation on serum prostate-specific antigen. Br J Urol 75: 498-501
47. Optenberg SA, Thomson IM 1990 Economics of screening for carcinoma of prostate. Urol Clin North Am 17: 719-737
48. Osterling JE 1991 Prostate-specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907-923
49. Ota K, Yamashita N, Suzuki T, Agishi T 1981 Malignant tumors in dialysis patients: a nationwide survey. Proc Eur Dial Transplant Assoc 18: 724-730
50. Partin A, Carter, Chan D, Epstein J, Oesterling J, Rock R, Weber J Walsh P 1990 Prostate-specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143: 747-752
51. Port F, Ragheb N, Schwartz A, Hawthorne V 1989 Neoplasms in dialysis patients: a population-based study. Am J Kidney Dis 14: 119-123
52. Reboll L, Cruz JF, Monfort JJ, Plumed J, Pallardo L 1996 Prostatism in patients with chronic renal failure and renal transplant recipients. Comparative study. Actas Urol Esp 20: 690-696
53. Rifkin M 1987 Endorectal sonography of the prostate: clinical implications. AJR 48: 1137-1142
54. Stamey T, Yang N, Hay A, McNeal J, Freiha F, Redwine E 1987 Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317: 909-916
55. Taneja SS, Tran K, Lepor H 2001 Volume-specific cut-offs are necessary for reproductive application of prostate-specific antigen density of the transition zone in prostate cancer detection. Urology 58: 222-227
56. US Renal Data System USRDS 1999 Annual Data Report. National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
57. Vamvakas S, Bahner U, Heidland A 1998 Cancer in end-stage renal disease: potential factors involved. Am J Nephrol 18: 89-95
58. Weinstein M, Epstein, J 1993 Significance of high-grade prostatic intra-epithelial neoplasia on needle biopsy. Hum Pathol 24: 624-629
59. Wills M, Hamper U, Partin A, Epstein J 1997 Incidence of high-grade prostatic intra-epithelial neoplasia in sextant biopsy specimens. Urology 49: 367-373